Discovery of a first-in-class reversible DNMT1-selective inhibitor

被引：0
|
作者：
Pappalardi, Melissa B. [1 ]
机构：
[1] GlaxoSmithKline, Collegeville, PA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3265
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)
    Zhou, Han-Jie
    Wang, Jinhai
    Yao, Bing
    Wong, Steve
    Djakovic, Stevan
    Kumar, Brajesh
    Rice, Julie
    Valle, Eduardo
    Soriano, Ferdie
    Menon, Mary-Kamala
    Madriaga, Antonett
    von Soly, Szerenke Kiss
    Kumar, Abhinav
    Parlati, Francesco
    Yakes, F. Michael
    Shawver, Laura
    Le Moigne, Ronan
    Anderson, Daniel J.
    Rolfe, Mark
    Wustrow, David
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (24) : 9480 - 9497
  • [32] Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
    Wang, Liguo
    Shao, Xuejing
    Zhong, Tianbai
    Wu, Yue
    Xu, Aixiao
    Sun, Xiuyun
    Gao, Hongying
    Liu, Yongbo
    Lan, Tianlong
    Tong, Yan
    Tao, Xue
    Du, Wenxin
    Wang, Wei
    Chen, Yingqian
    Li, Ting
    Meng, Xianbin
    Deng, Haiteng
    Yang, Bo
    He, Qiaojun
    Ying, Meidan
    Rao, Yu
    NATURE CHEMICAL BIOLOGY, 2021, 17 (05) : 567 - 575
  • [33] Discovery of a first-in-class, potent, selective and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083)
    Zhou, Han-Jie
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [34] FDA approves first-in-class AKT inhibitor
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (01) : 9 - 9
  • [35] FDA approves first-in-class SYK inhibitor
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (06) : 385 - 385
  • [36] FDA approves first-in-class AKT inhibitor
    Asher Mullard
    Nature Reviews Drug Discovery, 2024, 23 : 9 - 9
  • [37] Structural characterization of dicyanopyridine containing DNMT1-selective, non-nucleoside inhibitors
    Horton, John R.
    Pathuri, Sarath
    Wong, Kristen
    Ren, Ren
    Rueda, Lourdes
    Fosbenner, David T.
    Heerding, Dirk A.
    McCabe, Michael T.
    Pappalardi, Melissa B.
    Zhang, Xing
    King, Bryan W.
    Cheng, Xiaodong
    STRUCTURE, 2022, 30 (06) : 793 - +
  • [38] FDA approves first-in-class SYK inhibitor
    Asher Mullard
    Nature Reviews Drug Discovery, 2018, 17 : 385 - 385
  • [39] Romosozumab: A first-in-class scierostin inhibitor for osteoprosis
    Prather, Caitlin
    Adams, Erin
    Zentgraf, Whitney
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (23) : 1949 - 1956
  • [40] In vitro and in vivo induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor
    Gilmartin, Aidan G.
    Groy, Arthur
    Gore, Elizabeth R.
    Atkins, Charity
    Long, Edward R.
    Montoute, Monica N.
    Wu, Zining
    Halsey, Wendy
    McNulty, Dean E.
    Ennulat, Daniela
    Rueda, Lourdes
    Pappalardi, Melissa B.
    Kruger, Ryan G.
    McCabe, Michael T.
    Raoof, Ali
    Butlin, Roger
    Stowell, Alexandra
    Cockerill, Mark
    Waddell, Ian
    Ogilvie, Donald
    Luengo, Juan
    Jordan, Allan
    Benowitz, Andrew B.
    HAEMATOLOGICA, 2021, 106 (07) : 1979 - 1987
12345